Core Insights - Insight Molecular Diagnostics Inc. has submitted GraftAssureDx, a kitted dd-cfDNA assay, to the FDA for regulatory review, marking a significant milestone after 12 years of clinical development and 3 years of technical product development [1] - The company has seen a doubling in interest from transplant centers, now engaging with 37 centers in the U.S. and 11 internationally, which represents over 25% of annual transplants in the U.S. [3][4] - The addressable market for regulated transplant rejection testing is estimated at around $2 billion, with the company positioned to lead in this emerging market [4][5] FDA Submission and Market Readiness - The FDA has a 150-day review process for de novo submissions, and the company anticipates receiving authorization within this timeframe [5] - The company has prepared a review-ready submission with sufficient analytical data and clinical evidence to support the assay's safety and effectiveness [8] - The company expects to receive U.K. CE marking via self-certification in Q2 2026 [6] Financial Overview - For the full year 2025, the company reported revenue of $4.1 million, up from $1.9 million in 2024, with Q4 2025 revenues at $1.1 million [30] - The gross profit for 2025 was $2.3 million, reflecting a gross margin of 56.7%, compared to a gross profit of $740,000 in the previous year [32] - Operating expenses for 2025 totaled $53.4 million, including significant non-cash impairment losses [32] Research and Development - Research and development expenses increased by 62% year-over-year to $15.9 million, reflecting investments in kitted product development [32] - The company is also focusing on expanding GraftAssure's utility into heart transplantation, supported by a recent $26 million financing [6][12] Clinical Utility and Market Trends - The company believes that the organ transplant rejection testing market is shifting towards active management of patients post-transplant, enabling earlier detection of organ rejection [17] - The GraftAssure assay is designed to measure both absolute and relative quantities of dd-cfDNA, potentially improving the detection of T-cell mediated rejection [21][22] - The company anticipates that the demand for decentralized molecular testing will continue to grow, supported by emerging clinical data and publications [5][16] Strategic Goals for 2026 - The company aims to transition into a commercialization-stage company in 2026, with goals including obtaining regulatory approval for GraftAssureDx and commencing sales of the research-use-only version of its kits [12][13] - The company plans to engage 50 U.S. transplant centers for its GALACTIC registry study, which will help build a scientific case for the combined score of dd-cfDNA measurements [13]